Articles by Jill Wechsler - Pharmaceutical Executive


Articles by Jill Wechsler

Jill Wechsler

Washington Editor

Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on government policies and a wide range of topics for business and consumer publications.

Social Media Struggles Continue
August 1, 2014

Tweeting limited, corrections okay, says FDA, as industry, regulators wrestle with the digital world. Our Washington Correspondent Jill Wechsler reports.

Pre-emption and States' Rights
July 23, 2014

Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.

What Price Innovation?
June 16, 2014

Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.

Compassionate Use Requests Complicate Drug Development
June 1, 2014

Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.

Reimbursement Limits Threaten Drug Access
May 22, 2014

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

Obama Policies Reshape Pharma Marketing
April 10, 2014

Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.

Manufacturers Struggle with FDA's "Breakthrough Drug" Development
March 21, 2014

Accelerated testing and production create challenges in documenting product quality, writes Jill Wechsler.

Data disclosure, integrity challenge pharma
March 1, 2014

Transparency initiatives are multiplying, affecting research, marketing and compliance.

The Push for Transparency: Risks, Costs, and Concerns
February 26, 2014

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.


Click here